PT 107

Drug Profile

PT 107

Alternative Names: PT-107

Latest Information Update: 23 Jun 2015

Price : $50

At a glance

  • Originator Pique Therapeutics
  • Developer Pique Therapeutics; Technomark Life Sciences
  • Class Antineoplastics; Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 23 Jun 2015 Phase-II ongoing for non-small cell lung cancer in USA and India
  • 04 Jun 2013 Phase-II development is ongoing in USA & India
  • 21 Feb 2011 Phase-II clinical trials in Non-small cell lung cancer in India (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top